Curated News
By: NewsRamp Editorial Staff
July 24, 2025
Aditxt's Pearsanta Advances Ovarian Cancer Test with DoD Grant Opportunity
TLDR
- Aditxt's subsidiary Pearsanta, Inc. could gain a competitive edge with the Mitomic Ovarian Test, potentially securing a $350,000 grant for early ovarian cancer detection innovation.
- Pearsanta, Inc. plans to validate the Mitomic Ovarian Test through a multi-center clinical study, aiming for commercial launch as a laboratory-developed test with DoD funding.
- The Mitomic Ovarian Test by Pearsanta, Inc. represents a leap forward in women's health, offering hope for early detection and better outcomes in ovarian cancer.
- Discover how Aditxt's Pearsanta, Inc. is revolutionizing ovarian cancer detection with a novel blood-based test, backed by a potential $350,000 DoD grant.
Impact - Why it Matters
This news is pivotal as it highlights a significant advancement in the early detection of ovarian cancer, a disease known for its late diagnosis and high mortality rates. The development of the Mitomic(R) Ovarian Test (MOT(TM)) by Pearsanta, Inc., a subsidiary of Aditxt, represents a potential breakthrough in women's health, offering hope for earlier intervention and better outcomes. The involvement of the U.S. Department of Defense underscores the test's importance and the trust in its scientific merit and innovation. For investors and stakeholders in the health technology sector, this announcement signals Aditxt's growing influence and commitment to addressing critical health challenges through collaborative innovation.
Summary
Aditxt (NASDAQ: ADTX), a leading social innovation platform in the health technology sector, has announced a significant milestone for its subsidiary, Pearsanta, Inc. Pearsanta has been invited to submit a full proposal for the U.S. Department of Defense’s OCRP Pilot Award, following a favorable review of its pre-proposal for the Mitomic(R) Ovarian Test (MOT(TM)). This innovative blood-based diagnostic aims to revolutionize early detection of ovarian cancer. The potential grant of up to $350,000 over two years would support a multi-center clinical study to validate the test and prepare for its commercial launch as a laboratory-developed test. This development underscores Aditxt's commitment to advancing health technologies through its unique innovation platform, which collaborates with research institutions, industry partners, and shareholders to address significant societal health challenges.
Aditxt's ecosystem is designed to democratize innovation, ensuring that every stakeholder's voice is heard and valued. The company is currently focusing on immune health and precision health programs, with plans to expand into public health and women’s health. Strategic partnerships, including arrangements with Appili Therapeutics Inc. and a merger agreement with Evofem, highlight Aditxt's ambitious roadmap to tackle urgent health challenges. For more details on this groundbreaking initiative, visit the full press release here.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Aditxt's Pearsanta Advances Ovarian Cancer Test with DoD Grant Opportunity
